Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Patients hospitalized in ICU~* Patients under mechanical ventilation~* Patients with an expected length of stay of at least 4 days after inclusion~* Patients identified with an MDRB digestive carriage, determined by a positive rectal swab previously performed during ICU stay, according to usual screening~* Expected antibiotic (ATB) duration \< 10 days~* Informed written consent from the patient~* In unconscious patients who are not able to give consent for inclusion in the study, relatives (next-of-kin) give assent on every patient's behalf, and patients will be later given the opportunity to withdraw from the study~Exclusion Criteria:~* Patients with a high risk of death within 5 days according to investigator's opinion, or subjected to therapeutic limitation decisions~* Antibiotherapy of more than 4 consecutive days at inclusion~* Confirmed or suspected intestinal ischemia~* Confirmed or suspected toxic megacolon or gastrointestinal perforation~* Any gastro-intestinal bleeding in the past 3 months~* Any history of abdominal surgery in the past 3 months~* Any history of chronic digestive disease or gastro-intestinal resection~* Any counter indication for Trendelenburg position~* Neutropenia (neutrophil counts \< 500 cells/µL)~* Ongoing immunosuppressive therapy (chemotherapy, any immunosuppressive agents, excluding corticosteroids \< 0,5 mg/kg/d of equivalent prednisolone)~* Enrollment in another trial that may interfere with this study~* Known allergy or intolerance to trehalose or maltodextrin and latex~* Pregnancy or breastfeeding~* Patients with EBV- serology

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treated patients (Type: EXPERIMENTAL): Treated wit FMT

Based on this trial design, predict the completion outcome and termination type (if applicable).